SANTA CLARA, Calif., March 18, 2013 /PRNewswire/ -- Finesse Solutions, Inc., Santa Clara, CA, a manufacturer of measurement and control solutions for life science process applications, announced the release of TruBio® DV version 4.5 bioreactor control software that leverages its new SmartParts™ components. TruBio software can automate a wide variety of bioreactors, ranging from 0.5L bench-scale glass to 2,000L cGMP single-use production vessels. Since its first launch in 2007, TruBio DV continues to be powered by a DeltaV® Controller from Emerson Process Management; TruBio DV version 4.5 is optimized for DeltaV version 11.3.
"For highly demanding upstream applications, it's critical to have an architecture built for flexibility and cost effective integration of different vessels. TruBio DV software can be used with glass vessels, rockers, mixer, and most sizes/brands of single-use bioreactors to provide a seamless solution from R&D through production," stated Dr.
Barbara Paldus, CEO of Finesse.
TruBio DV 4.5 has been enhanced to leverage Finesse's new SmartParts family of intelligent digital actuators, and is pre-configured with new modules for high accuracy gas and liquid delivery into upstream bioprocesses. SmartMFC™ algorithms improve flow accuracy while minimizing energy consumption; SmartPump™ algorithms enable gravimetric pump dosing with scale feedback or a feed functions including continuous, ramp and bolus. TruBio can also overlay on third party equipment for data harmonization or more sophisticated control of older controllers with limited performance.
"To further illustrate the power of TruBio DV 4.5 software we must also look at its new measurement capabilities: tridundant pH/DO and dual pressure sensors that can be any combination of traditional and single-use; integration of third party sensors via analog output or Modbus; and OPC communication with off-line analyzers and sampling systems. TruBio offers the only truly "open" control environment for process development and scale-up, without sacrificing the ability for cGMP technology transfer," added Dr. Selker, VP R&D and co-founder of Finesse.